Ophthalmic Pharmaceutical Drugs - A Global Market Perspective
NEW YORK, Jan. 29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Ophthalmic Pharmaceutical Drugs - A Global Market Perspective
Prevention of blindness has emerged into a top health priority among aging citizens in the developed countries. And increased healthcare spending in these countries is creating a strong demand for advanced ophthalmic therapeutic treatments. This in turn is leading to the rise in investments in ophthalmic drug research, and a parallel spurt in the commercial availability of innovative and promising ocular drugs. Ongoing research studies on developing pharmacologic IOP reducing drugs is expected to lead to the availability of powerful topical drugs with lesser side effects, and higher therapeutic efficacies, thereby overthrowing the present bottleneck of low patient compliance. Pharmacodiversity and newer classes of potent drugs together, are expected to encourage patient compliance, and improve patient outcomes. The market therefore is expected to get a much-awaited respite from the business, and economic repercussions of low patient compliance.
These and other market data and trends are presented in "Ophthalmic Pharmaceutical Drugs: A Global Market Perspective" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
OPHTHALMIC PHARMACEUTICAL DRUGS BMR-1041
CONTENTS
1. METHODOLOGY 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Quantitative Techniques & Reporting Level 3
2. INDUSTRY OVERVIEW 4
A Curtain Raiser 4
Drugs Developed in the Recent Past 4
What the Future Holds in Store? 5
Where Does the Opportunity Lie? 5
In the Shifting Demographics 5
Which Disease Segment Offers Abundant Opportunities for R&D
Initiatives 6
Leading Companies & Their Areas of Research Interest/Focus 7
Business Opportunities in Ophthalmology: A Fact Sheet 8
Impediments in Picking the Ripe & Low Hanging Opportunities 8
Low Patient Compliance 8
What's the Antidote to Low Patient Compliance? 9
Innovation in Ophthalmic Pharmaceuticals: How Does It Help
Patients? 9
An Unequivocal Discussion About Ocular Drug Design and Delivery 10
Why Understanding of the Metabolic Activity of the Eye is
Important? 10
Pitfalls of Traditional Ocular Treatment 11
Ophthalmic Drug Delivery: A Recapitulation of Facts 12
Antidotes to Low Delivery of Ocular Drugs & High Side Effects 13
Prodrug 14
Soft Drugs (SDs) 14
Soft Corticosteroids 15
Drug Penetration Enhancers 15
Chitosan Based Drugs & Drug Delivery Systems 15
How Chitosan is used to Improve Ocular Drug Retention- On
the Eye's Surface? 16
The Future of Ophthalmic Drug Delivery 17
A Straight Talk About Ophthalmic Drug Delivery Technologies 17
High Flying Expectations of Blistering Pace of Drug
Development- Grounded 17
First Generation Advancements Made in Ocular Drugs 18
Second Generation Advancements Made in Ocular Drugs 19
Limiting Factors 20
3. MARKET DYNAMICS 21
Ophthalmic Pharmaceuticals Poised to Encounter Days of Plenty 21
Ophthalmic Inserts Flaunt the Potential to Eclipse the
Popularity of Eye Drops 21
Rising Incidences of Glaucoma: A Business Case for Ophthalmic
Drugs 22
Aging Population & Environmental Factors Drive Growth 22
Increase in Health Care Spending 23
Opportunities Abound in the Developing Countries 23
Innovative Products Lend Traction to Growth 24
Reimbursements: "Under the Umbrella" 24
4. PRODUCT FACTS 25
5. CORPORATE DEVELOPMENTS 27
Bausch & Lomb Acquires IOL Maker, Eyeonics 27
Akorn Inks Manufacture & Supply Agreement for Ophthalmic Solution 27
CrystalGenomics Enters Into R&D Agreement with Bausch & Lomb 27
Genaera Corporation Quits Evizon Clinical Trials 27
Eyetech Inc Divests Anti-Platelet Derived Growth Factor (PDGF)
Aptamer- Program 27
Amneal, Indoco Agree to Develop & Market Generic Ophthalmic Drugs 28
Bausch & Lomb Acquire Soothe Products from Alimera 28
Froptix, Acuity, eXegenics Merge to Form Opko Corporation 28
Alimera, Emory Collaborate Over Potential Ophthalmic
Treatments Using Novel Antioxidants 28
Santen Signs Agreement with Vistakon Pharmaceuticals for US
Launch of Iquix® 29
Inspire Pharmaceuticals Rolls Out AzaSite™ for Ocular Infections 29
QLT Takes Over Forsight Newco II, Inc 29
Inspire Pharmaceuticals Rolls Out AzaSite™ for Ocular Infections 29
Novagali Obtains FDA Approval of Nova22007 IND for Ph III Trial 30
Alimera Conducts Phase III Medidur Trial 30
ISTA Pharmaceuticals Files NDA for Xibrom™ QD 30
AzaSite Receives FDA Approval 30
6. MAJOR PLAYERS 31
Akorn, Inc (USA) 31
Alcon Eye Care, Inc (USA) 31
Allergan, Inc. (USA) 31
Alimera Sciences, Inc (USA) 31
Bausch & Lomb, Inc (USA) 31
Genvec, Inc (USA) 32
Glaxosmithkline Plc (UK) 32
Inspire Pharmaceuticals, Inc (USA) 32
Ista Pharmaceuticals, Inc (USA) 32
Merck & Co., Inc (USA) 32
Opko Health, Inc (USA) 33
Otsuka Pharmaceutical Co., Ltd (JAPAN) 33
Pfizer Inc (USA) 33
QLT, Inc. (Canada) 33
Santen Pharmaceutical Co. (Japan) 33
Santen Inc. (US) 33
7. GLOBAL MARKET ANALYTICS 34
8. THE UNITED STATES 42
Emphasis on Greater Awareness About Ophthalmic Disorders 42
Growth Drivers In a Capsule 43
Impediments to Growth 43
Market Fact Sheet 43
Glaucoma Market: A Primer 44
Awareness Among Patients 44
High Costs 45
Treatment Patterns Adopted By Doctors 45
The All Consuming Issue of Compliance 45
Market Share Statistics 46
The New Batting Order 46
Update On Drugs & Their Manufacturers in the US 49
Patent Expirations of Key Ophthalmic Product Brands in the
United States 49
Statistical Findings On Ophthalmic Diseases in the United States 50
9. CANADA 53
Lack of Awareness: A Key Issue 53
10. JAPAN 55
Growth Drivers 55
Market Data Statistics 55
11. EUROPE 57
a. France 61
b. Germany 62
c. The United Kingdom 63
d. Italy 64
e. Spain 65
f. Rest of Europe 68
12. ASIA-PACIFIC 69
13. LATIN AMERICA 70
14. REST OF WORLD 71
EXHIBITS
Table 1: Prevalence of Glaucoma in the World -2006 (In 000
Individuals)
Table 2: Global Ophthalmic Pharmaceutical Drugs Market by
Region for the Period 2007-2015 (Sales in US$ Million)
Table 3: Percentage Breakdown of Global Ophthalmic
Pharmaceutical Drugs Market by Region for the Years 2008 &
2012
Table 4: Global Glaucoma Market by Region for the Period
2007-2015 (Sales in US$ Million)
Table 5: Percentage Breakdown of Global Glaucoma Market by
Region for the Years 2008 & 2012
Table 6: Global Anti-allergy Market by Region for the Period
2007-2015 (Sales in US$ Million)
Table 7: Percentage Breakdown of Global Anti-allergy Market by
Region for the Years 2008 & 2012
Table 8: Global Anti-infective Market by Region for the Period
2007-2015 (Sales in US$ Million)
Table 9: Percentage Breakdown of Global Anti-infective Market
by Region for the Years 2008 & 2012
Table 10: Global Dry Eye Market by Region for the Period
2007-2015 (Sales in US$ Million)
Table 11: Percentage Breakdown of Global Dry Eye Market by
Region for the Years 2008 & 2012
Table 12: Global Anti-inflammation Market by Region for the
Period 2007-2015 (Sales in US$ Million)
Table 13: Percentage Breakdown of Global Anti-inflammation
Market by Region for the Years 2008 & 2012
Table 14: Global Back of Eye Market by Region for the Period
2007-2015 (Sales in US$ Million)
Table 15: Percentage Breakdown of Global Back of Eye Market by
Region for the Years 2008 & 2012
Table 16: Global Other Treatment Category Market by Region for
the Period 2007- 2015 (Sales in US$ Million)
Table 17: Percentage Breakdown of Global Other Treatment
Category Market by Region for the Years 2008 & 2012
Table 18: Market Shares of Leading Players in the US Market
for Ophthalmic Pharmaceutical Drugs - 2007E
Table 19: Breakdown of Top 10 Eye/ Lens Care Brands in the US
- 2007
Table 20: Breakdown of Top 5 Eye Care Products in the US -
2007
Table 21: Market Shares of Leading Players in the US
Age-Related Wet Macular Degeneration Market -2006
Table 22: Market Shares of Leading Players in the US Ocular
Allergy Market -2007E
Table 23: Market Shares of Leading Players in the US Market
for Ocular NSAIDs (Topical Non-Steroidal Anti-Inflammatory
Drugs) - 2006
Table 24: Dollar Sales of Major Branded Drugs in the US Market
for Age-Related Macular Degeneration - 2009 & 2012
Table 25: Prevalence of Age-Related Wet Macular Degeneration
in the US - 2009 & 2012
Table 26: Number of Individuals Treated for Wet AMD in the US-
2009 & 2012
Table 27: Prevalence of Ocular Hypertension (OHT) in the US-
2009 & 2011
Table 28: Prevalence of Primary Open Angle Glaucoma (POAG) in
the US - 2009 & 2011
Table 29: Prevalence of Normal Tension Glaucoma (NTG) in the
US - 2009 & 2011
Table 30: Prevalence of Exfoliative Glaucoma (EG) in the
United States for the Years 2009 & 2011 (In Thousand
Individuals)
Table 31: Prevalence of Pigmentary Glaucoma (PG) in the
United States for the Years 2009 & 2011 (In Thousand
Individuals)
Table 32 Breakdown of Number of Individuals Treated for
Glaucoma by Type in the United Sates - 2009 and 2011 (In 000
Individuals)
Table 33: Prevalence of Ocular Allergy in the United States
for the Years 2009 & 2012 (In Millions of Individuals)
Table 34: Number of Individuals Treated for Ocular Allergy in
the United States - 2009 & 2012
Table 35: Prevalence of Cataract in the US - 2009 & 2012
Table 36: Number of Individuals Treated for Cataract With
Ocular NSAIDs (Topical Non-Steroidal Anti-Inflammatory Drugs)
in the US - 2009 & 2012
Table 37: Prevalence of Dry Eye in the US - 2009 & 2012
Table 38: Number of Individuals Treated for Dry Eye in the US
- 2009 & 2012
Table 39: Ophthalmic Pharmaceutical Drugs Market by
Therapeutic Category in the US: 2007-2015 (Sales in US$
Million)
Table 40: Percentage Breakdown of Ophthalmic Pharmaceutical
Drugs Market by Therapeutic Category in the US for the Years
2008 & 2012
Table 41: Ophthalmic Pharmaceutical Drugs Market by
Therapeutic Category in Canada: 2007-2015 (Sales in US$
Million)
Table 42: Percentage Breakdown of Ophthalmic Pharmaceutical
Drugs Market by Therapeutic Category in Canada for the Years
2008 & 2012
Table 43: Percentage Breakdown of Japanese Market for
Prescription Ophthalmic Drugs by Therapeutic Area - 2005
Table 44: Ophthalmic Pharmaceutical Drugs Market by
Therapeutic Category in Japan: 2007-2015 (Sales in US$
Million)
Table 45: Percentage Breakdown of Ophthalmic Pharmaceutical
Drugs Market by Therapeutic Category in Japan for the Years
2008 & 2012
Table 46: Ophthalmic Pharmaceutical Drugs Market by Region in
Europe: 2007-2015 (Sales in US$ Million)
Table 47: Percentage Breakdown of Ophthalmic Pharmaceutical
Drugs Market by Region in Europe for the Years 2008 & 2012
Table 48: Ophthalmic Pharmaceutical Drugs Market by
Therapeutic Category in Europe: 2007-2015 (Sales in US$
Million)
Table 49: Percentage Breakdown of Ophthalmic Pharmaceutical
Drugs Market by Therapeutic Category in Europe for the Years
2008 & 2012
Table 50: Ophthalmic Pharmaceutical Drugs Market by
Therapeutic Category in France: 2007-2015 (Sales in US$
Million)
Table 51: Percentage Breakdown of Ophthalmic Pharmaceutical
Drugs Market by Therapeutic Category in France for the Years
2008 & 2012
Table 52: Ophthalmic Pharmaceutical Drugs Market by
Therapeutic Category in Germany: 2007-2015 (Sales in US$
Million)
Table 53: Percentage Breakdown of Ophthalmic Pharmaceutical
Drugs Market by Therapeutic Category in Germany for the Years
2008 & 2012
Table 54: Ophthalmic Pharmaceutical Drugs Market by
Therapeutic Category in the UK: 2007-2015 (Sales in US$
Million)
Table 55: Percentage Breakdown of Ophthalmic Pharmaceutical
Drugs Market by Therapeutic Category in the UK for the Years
2008 & 2012
Table 56: Ophthalmic Pharmaceutical Drugs Market by
Therapeutic Category in Italy: 2007-2015 (Sales in US$
Million)
Table 57: Percentage Breakdown of Ophthalmic Pharmaceutical
Drugs Market by Therapeutic Category in Italy for the Years
2008 & 2012
Table 58: Ophthalmic Pharmaceutical Drugs Market by
Therapeutic Category in Spain: 2007-2015 (Sales in US$
Million)
Table 59: Percentage Breakdown of Ophthalmic Pharmaceutical
Drugs Market by Therapeutic Category in Spain for the Years
2008 & 2012
Table 60: Ophthalmic Pharmaceutical Drugs Market by
Therapeutic Category in Rest of Europe: 2007-2015 (Sales in
US$ Million)
Table 61: Percentage Breakdown of Ophthalmic Pharmaceutical
Drugs Market by Therapeutic Category in Rest of Europe for
the Years 2008 & 2012
Table 62: Ophthalmic Pharmaceutical Drugs Market by
Therapeutic Category in Asia-Pacific: 2007-2015 (Sales in US$
Million)
Table 63: Percentage Breakdown of Ophthalmic Pharmaceutical
Drugs Market by Therapeutic Category in Asia-Pacific for the
Years 2008 & 2012
Table 64: Ophthalmic Pharmaceutical Drugs Market by
Therapeutic Category in Latin America: 2007-2015 (Sales in US$
Million)
Table 65: Percentage Breakdown of Ophthalmic Pharmaceutical
Drugs Market by Therapeutic Category in Latin America for the
Years 2008 & 2012
Table 66: Ophthalmic Pharmaceutical Drugs Market by
Therapeutic Category in Rest of World: 2007-2015 (Sales in US$
Million)
Table 67: Percentage Breakdown of Ophthalmic Pharmaceutical
Drugs Market by Therapeutic Category in Rest of World for the
Years 2008 & 2012
COMPANIES PROFILED
To order this report:
Pharmaceutical Industry: Ophthalmic Pharmaceutical Drugs - A Global Market Perspective
Check our Company Profile, SWOT and Revenue Analysis!
Contact:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article